Search Results

Analysts at William Blair expect drug developers will continue to perform “at least some animal testing” on their investigational products. Though the process to phase out animal testing will begin “immediately,” no specific timetable was given.

Heart Test Laboratories, Inc.d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”) today reported financial results for the third quarter fiscal 2024 ended January 31, 2024 and provided a business update.

Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that Chief Executive Officer Andrew Simpson is scheduled to present at the LD Micro Invitational XIV Conference on Tuesday April 9, 2024 at 5:00pm ET at the Sofitel New York.

Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”) today announced that the Canadian Intellectual Property Office Application No. 3,000,369 has been granted by the Canadian Intellectual Property Office.

Heart Test Laboratories, Inc. d/b/a HeartSciences, an artificial intelligence -powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced the appointment of Jordan B. Strom M.D., M.Sc., to its Scientific Advisory Board.

Heart Test Laboratories, Inc. d/b/a HeartSciences, an artificial intelligence -powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced the publication, in Cardiovascular Diabetology, of an independent, peer-reviewed study utilizing its MyoVista® proprietary technology.

Heart Test Laboratories, Inc. d/b/a HeartSciences, an artificial intelligence -powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced the appointment of Benjamin Glicksberg, Ph.D. to its Scientific Advisory Board.

Heart Test Laboratories, Inc.d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”) today reported financial results for the second quarter fiscal 2024 ended October 31, 2023 and provided a business update.